skip to main content

brainstorm askiatroX medicines

simulations beta

loading page…

learn & practise

exams international doctors free questions Socratic Tutor rounds stat clinical connections academy journal tool guides

clinical reference

askiatroX knowledge centre medicines UK / NICE guidance international guidance calculators q&a library

trust & support

how it works methodology account & support frequently asked questions about us clinical safety consultancy

legal

mobile app · scan to download

Medicines ocrelizumabQuestion & answer

ocrelizumab · Medicine question

Is ocrelizumab contraindicated in patients with known active malignancies?

iatroX medicinesPublished 8 November 2026

The answer

Answer

Yes, ocrelizumab is contraindicated in patients with known active malignancies.

Sources for this answer

OCREVUS 300 mg concentrate for solution for infusionRoche Products Limited · emc · SmPC §4.3 Contraindications · Version 22Document updated 29 September 2026

Sources checked 8 November 2026

Explore this learning need in CPDTake this topic to CPD, then choose your learning context and available question library.

The full medicine guide

More questions about ocrelizumab

Can neutropenia occur several months after ocrelizumab administration?Can ocrelizumab be used during breastfeeding?Does ocrelizumab affect the ability to drive or use machines?How does ocrelizumab act on CD20-expressing B cells?How is Ocrevus (ocrelizumab) 300 mg concentrate for solution for infusion administered?How long after an ocrelizumab infusion can infusion-related reactions occur?

ocrelizumab

Read the wider context, including uses, precautions and the sources behind this medicine guide.

Read the ocrelizumab guide

More clinical questions?

Explore the tools and reference material available on iatroX.

Explore askiatroX